Christine Aylward, founder & Managing Partner
Christine Aylward founded Magnetic Ventures in 2018 and focuses on early stage investing at the intersection of life science and technology. She has worked at the forefront of healthcare innovation since the start of her career and has been in the venture capital business since 2011. Christine has a proven track record of investing in healthcare winners, deep domain expertise, and industry operating experience commercializing global franchises and building companies. She started her career at Roche where she launched the revolutionary technology polymerase chain reaction (PCR), formed the first cross collaboration between the pharmaceutical and diagnostic divisions, was a key member of several marketing teams at Roche Pharmaceuticals, Roche Diagnostics and Roche Molecular Systems, and was placed on the Executive Development Track. Christine has helped launch more than 20 products in the pharmaceutical, genomics, technology and diagnostic sectors. As an Advisor to start-ups and entrepreneurs she has worked with sector-leading companies such as Genomic Health, Salix Pharmaceuticals, WebMD, Celera, and Intarcia.
Most recently, Christine was a Managing Director, member of the investment team, and head of Business Development at Foresite Capital. While there, Christine was instrumental in building the firm to $1.2 billion in assets under management over five years, and helped identify and grow some of the most valuable companies within the portfolio, including Aimmune and 10x Genomics. Christine has also been an entrepreneur in the media sector, and was a partner at a technology-focused investment bank acquired by Goldman Sachs. As a founder, business executive and investor, Christine not only has a unique lens to evaluate companies but is also an invaluable resource for the entrepreneurs in which she invests. Her meaningful relationships and expertise span pharmaceuticals, diagnostics, genomics, technology, and finance.
Christine is a Member of the Board of Directors for UCSF Health Hub and is a Senior Advisor to TPG Growth and the Rise Fund.
Richard Evans, D.V.M., Venture Partner
Richard Evans is an industry expert with more than 25 years experience. Richard and Christine have known each other since Roche and he joined Magnetic as a Venture Partner in 2018. He is also the Founder and General Manager of SSR Health LLC, a boutique sell-side investment research firm. Richard served as a Senior Analyst covering the US pharmaceuticals industry at Sanford C. Bernstein & Co., LLC, from 1998 until 2006, and was twice ranked first amongst his peers for drug stock selection by Bloomberg, and in 2006 was ranked amongst the top 20 stock pickers globally, also by Bloomberg. He was named to the Institutional Investor’s All-America Research Team for much of his tenure with Bernstein, ranking first for major pharmaceuticals in 2006. His work has been highlighted in various major media outlets, including The Wall Street Journal, Barron's, The New York Times, Fortune, CNN, CBS, and Frontline.
Previously, he was a member of senior management at Roche Pharmaceuticals, serving most recently as vice president, Business Policy and Account Management. In this capacity, he was responsible for Roche's commercial interactions with large organized buyers such as hospitals, hospital purchasing groups, managed-care organizations and governments. His responsibilities also included those areas of the company which define and support account interactions, namely account management, customer marketing, pricing, contract administration, pharmacoeconomics, and distribution. During his seven years at Roche, Dr. Evans also served as the head of Business Development and Strategic Planning, and as product director for the company's injectable anesthetics. He earned a doctorate in Veterinary Medicine from North Carolina State University in 1988 and a master of Public and Private Management from Yale University in 1991.